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Abstract
Introduction—The results of a 2001–2005 polycythemia vera (PV) investigation in Eastern 
Pennsylvania revealed a disease cluster plus underreporting and false reporting to the Pennsylvania 
Cancer Registry (PCR).
Purpose—The objectives of this study were 1) to assess PV reporting to the PCR in 2006–2009, 
2) to determine whether a cancer cluster persisted, and 3) to determine whether other 
myeloproliferative neoplasms (MPNs), including essential thrombocytopenia (ET), were subject to 
similar reporting problems.
Methods—Cases were identified from: 1) PCR records from the Tri-County, 2) reviewing billing 
records at Tri-County hematologist/oncologist offices, and 3) self-identification. An expert panel 
of physicians reviewed medical records and determined “true,” “false,” or “indeterminate” cases 
reported to the PCR. The analyses were conducted to determine sensitivity and positive predictive 
value (PPV) of case reporting to the PCR, estimate cancer incidence rates, and evaluate the 
presence of cancer clusters.
Results—Of 290 cases identified, 90% were from the original PCR, 9% from billing records, and 
1% from self-report. Fifty-five cases consented to participate, and medical records were obtained 
for 44. The expert panel determined that 45% were true cases, 32% were false cases, and 23% 
were indeterminate. PV had 100% (95% CI, 59–100) sensitivity, but only 47% PPV (95% CI, 20–
70): ET had 78% (95% CI, 47–99) sensitivity and 100% PPV (95% CI, 59–100). Low 
participation and chart review rates led to rates with wide confidence intervals. We did not identify 
any PV cancer clusters, but we did identify a cluster of 9 ET cases in the Wilkes-Barre, 
Pennsylvania area.
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Conclusion—The current study was limited by the low response rate (22%) from MPN patients 
in the Tri-County area. This study identified 47% PPV for PV reporting and 100% PPV for ET.
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Background
Polycythemia vera (PV), a chronic hematologic malignancy involving an overproduction of 
red blood cells, belongs to a class of neoplasms classified by the World Health Organization 
(WHO) as myeloproliferative neoplasms (MPNs). All of the MPNs are hematopoietic stem 
cell disorders of common clonal heritage, characterized by bone marrow proliferation and 
peripheral blood erythrocytosis, thrombocytosis, or granulocytoses.1 In addition to PV, the 
MPNs include chronic myeloid leukemia (CML), essential thrombocytopenia (ET), primary 
myeloid fibrosis (PMF), and other related and unclassifiable MPNs, such as chronic 
neutrophilic leukemia.1 In 2005, a somatic point mutation in the JAK2 gene of 
hematopoietic cells was discovered; this mutation, JAK2V617F, is found in more than 90% 
of persons with PV and in approximately 50% of persons with ET and PMF.2 Factors 
leading to this acquired genetic mutation are unknown.
In 2004, physicians and residents in the Tamaqua area of eastern Pennsylvania became 
concerned about the diagnosis of PV in 4 persons living on the same street with nearby toxic 
waste sites.3 In 2005, the Pennsylvania Department of Health (PADOH) determined a higher 
incidence of PV in Luzerne and Schuylkill counties. Upon request from PADOH, the 
Agency for Toxic Substances and Disease Registry (ATSDR) assessed sensitivity and 
positive predictive value (PPV) of PV reporting to the Pennsylvania Cancer Registry (PCR) 
for Luzerne, Schuylkill, and Carbon counties. ATSDR used findings to estimate PV 
incidence rates from 2001 (when MPNs first became reportable) through 2005 in these 3 
counties. The results of this evaluation indicated that inaccurate reporting of PV to the PCR 
led to PV risk estimates that were inflated over true values by 13% to 62%2. The ATSDR 
study did identify a statistically significant cluster of PV cases near the intersection of the 3 
counties. The incidence of PV in this cluster area was more than 4 times that of the entire 
Tri-County area3. Several hazardous waste exposure sites were identified near the cluster 
area.3 In 2009, Congress funded ATSDR to continue this investigation. ATSDR is 
overseeing 18 projects related to this cluster with partners including the PADOH, the 
Pennsylvania Department of Environmental Protection, and various universities and private 
organizations 4.
The MPNs represent an inter-related series of diseases that may have a common origin, and 
the entire spectrum of these diseases has not yet been evaluated in the Tri-County area. The 
current study was designed as an update and expansion of the original ATSDR study to 
determine if 1) sensitivity and PPV of PV reporting had improved in 2006–2009, 2) 
reporting of PMF, ET and related MPNs was complete and accurate in the Tri-County area 
for 2001–2009, and 3) rates of these related MPNs were elevated in the Tri-County area. The 
CML results are reported separately5.
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The first phase of case ascertainment consisted of obtaining information on all cases 
reported to the PCR with residence at time of diagnosis in Carbon (FIPS [Federal 
Information Processing Standards] code 42025), Luzerne (FIPS code 42079), or Schuylkill 
(FIPS code 42107) County and the following dates of diagnosis and histology codes: 2006–
2009 for PV (histology code 9950); 2001–2009 for ET (histology code 9962), PMF 
(histology code 9961), and MPN not otherwise specified (MPN/NOS) (histology code 
9960). Cases of acute panmyelosis with myelofibrosis (APMF) (histology code 9931) were 
also reviewed to determine whether PMF cases had been misclassified.
In the second phase of case identification (enhanced casefinding), PCR staff conducted 
active casefinding outreach by visiting all 9 hematologist/oncologist offices within the Tri-
County area and 2 in surrounding counties to ascertain cases that should have been reported 
to the PCR but were not in the PCR files. The PCR staff reviewed patient billing records 
from each office. PCR staff reviewed the medical records of patients with MPN-associated 
billing codes who were not already included in the PCR files, and abstracted and reported 
those eligible cases to study investigators. Persons with MPNs could also self-identify to 
study investigators and were informed about the study by press releases about the study, and 
had multiple opportunities to meet with investigators in person during visits to the Tri-
County area.
Data Collection
Potential cases were asked to participate in 3 phases of data collection: release of medical 
records related to their MPN diagnosis, a telephone survey, and a JAK2 mutation test (if one 
had not already been performed). Potential cases were mailed letters of introduction, consent 
forms, and releases for medical records (for review by the expert panel), and asked to return 
signed forms indicating their participation.
The study coordinator requested copies of outpatient and inpatient medical records relevant 
to the MPN diagnosis. The medical records submitted were reviewed. Incomplete medical 
record requests were also identified. The study coordinator telephoned the offices of medical 
providers and asked about the availability of medical records that appeared to be missing; 
multiple phone calls and repeated attempts to obtain records from noncompliant offices were 
made.
Patients not previously tested were asked to consent to JAK2 mutation testing. If they 
agreed, an appointment was scheduled at a local hospital for testing. A 10-cc blood sample 
was collected in an ethylenediaminetetraacetic acid (EDTA) blood collection tube and sent 
to the Division of Molecular Diagnostics, Department of Pathology, University of Pittsburgh 
Medical Center, for detection of the JAK2 mutation by allele-specific polymerase chain 
reaction.
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The 5-member expert panel consisted of 4 board-certified hematologist/oncologists and 1 
family practitioner. The study investigators assembled records received from medical 
providers and placed them in chronological order. Three expert panel members 
independently reviewed each case’s medical records. Expert panel members were instructed 
to review cases in 2 ways: 1) by applying conventional hematology practice standards at the 
time of diagnosis to determine the appropriateness or suitability of the diagnosis and 2) by 
classifying cases according to the 2008 WHO guidelines. Separate classification forms were 
developed for each disease. Expert panel members gave a determination for each case as 
“definitely” or “probably” a case (true cases), “possibly” a case (indeterminate), “definitely 
not” or “probably not” a case (false cases). At least 2 of the 3 opinions needed to be in 
agreement for true and false cases; if the members had different opinions or at least 2 
members were not in agreement, the case was classified as indeterminate.
Data Analysis
After cases were categorized as “true,” “indeterminate,” or “false,” we determined the 
sensitivity and PPV of the PCR. Sensitivity was calculated as the number of cases originally 
reported to the PCR divided by the total number of all true cases which includes those 
originally reported plus those found by reviewing billing records and self-report. PPV was 
calculated as the number of true cases originally reported to the PCR divided by the total 
number of cases, which included false positives, originally reported to the PCR. To adjust 
the PCR-reported incidence rates for sensitivity and PPV, we divided the Tri-County area 
incidence rate by the sensitivity then multiplied by the PPV. The 95% confidence intervals 
were calculated using the exact method.9
To identify geographic subregions with an elevated incidence of an MPN, we included true 
cases and ZIP code– and census tract-level population counts from the US 2000 Census 6 
with ZIP code or census tract centroids (calculated from US Census Bureau7 shape files 
using ArcGIS Version 9 tools). We used SaTScan (Version 7.0.3),8 designed to analyze 
spatial, temporal, and space-time data using the corresponding scan statistics, and we used 
the Poisson-based model for spatial data, as well as the space-time permutation model. The 
discrete Poisson-based model considers the number of events in a geographical location as 
Poisson-distributed, based on the underlying population at risk. Under the null hypothesis, 
the expected number of cases in each area is proportional to its population size, or person 
years. The analysis is then conditioned on the total number of cases observed. The space-
time permutation model uses only case data and scans for unusual occurrences in space and 
time simultaneously. ATSDR previously used the Poisson-based model for spatial data to 
identify a statistically significant primary geographic cluster of PV cases diagnosed in 2001–
2005 in a region with a history of environmental contamination.3 This study was approved 
by the Institutional Review Boards of the University of Pittsburgh and the Pennsylvania 
Department of Health.
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We identified a total of 290 potential MPN cases from the original PCR reports (n = 260), 
the enhanced casefinding (n = 25), and self-identification (n = 5). Overall, the original PCR 
data contributed approximately 90% of identified cases, with 42% reported as PV (Table 1). 
The PCR casefinding efforts identified an additional 25 cases, of which 56% (n = 14) were 
ET. Five cases self-identified to investigators: 4 PV cases and 1 ET case.
Case Participation
As shown in Figure 1, we determined a mailing address for 253, or 87%, of 290 cases. Of 
these, 58 consented (22%), 53 refused (21%), 2 (1%) were unable to consent, and 140 (55%) 
did not respond, despite numerous mailings and phone calls.
Over 90% of participants consenting to the study agreed to the interview (n = 54) and release 
of medical records (n = 55), but less than 20% consented to the blood draw (n = 10) (Figure 
1). Of the 55 participants who agreed to the release of medical records, we were not able to 
obtain records for 11 (20%). Some physician offices (%) did not send records (n = 6) or 
required proof of executorship from the deceased cases’ estates (n = 5).
Expert Panel Review and Case Determination
Forty-four medical records were sent to expert panel members for review. Of these, 20 
(45%) were determined to be true cases, 10 (23%) were indeterminate, and 14 (32%) were 
false (Figure 1). The expert panel members reached a unanimous opinion for 29 of the 44 
cases reviewed (66%). PV had the lowest agreement rate (52%; 11/21 unanimous opinion) 
(data not shown).
Sensitivity and PPV of PCR Reporting
Case determination status by histology is provided in Table 2. ET had the highest percentage 
determined to be true cases (67%), followed by MPN/not otherwise specified (NOS) (60%), 
and PV and PMF (33%). Of the 44 evaluated cases, 36 were originally reported to the PCR, 
3 were identified by review of billing records and 5 were self-identified. Seventeen of the 20 
true cases were from the PCR; 2 were from billing records (1 ET and 1 PMF); and 1 from 
self-identification (ET).
Additional information about the indeterminate and false judgments is provided in Table 3. 
The majority of the indeterminate determinations (n = 7; 70%) were due to not enough 
information being provided in the medical records regarding criteria used for diagnosis. Of 
the false cases, many were determined to have a non-MPN diagnosis, primarily secondary 
polycythemia in patients diagnosed with PV. One self-reported case was deemed 
indeterminate but was probably a secondary polycythemia case. Three self-reported cases 
were deemed false: 1 did not have enough information in the medical records for the experts 
to make a determination, 1 was determined to be a JAK2+ non-MPN, and 1 was an “other 
MPN” diagnosis (PMF).
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Table 4 shows the estimated sensitivity and PPV of the PCR. Sensitivity of the PCR was 
85% (17 true PCR cases out of 20 true cases found in the study). The PCR data file included 
all true cases of PV. We estimated sensitivity of PV at 100% given that we did not find any 
additional true PV cases by searching billing records. The only true PMF case identified was 
originally reported to the PCR as APMF (code 9931) and after review by the expert panel 
was determined to be PMF. One ET cases was identified by the additional PCR casefinding 
efforts and 1 self-identified, giving ET a sensitivity of 78% (7/9). PV had the lowest PPV of 
47% (7/15).
PV and Other MPN Incidence Rates
Shown in Table 5 are the original PCR incidence rates by histology, the study-determined 
sensitivity and PPV, and estimated incidence rates for comparison. As shown, our estimated 
ET incidence rate (2.3/100,000) is higher than the original PCR estimate (1.8/100,000). The 
other histologies have lower estimated incidence rates than those based on original case 
reporting. The estimated PV incidence rate showed the largest difference from the PCR-
derived rate, at 5.3/100,000 compared to 2.5/100,000.
GIS Analysis
We performed SaTScan analyses by ZIP code and census tract for the 2 histologic groups 
with 5 or more true cases (PV and ET). Using the 7 true PV cases, no statistically significant 
clusters were identified in space or in space-time (the model adjusts for any purely spatial 
and temporal variation) at either the ZIP code or census tract level.
Using the 9 true ET cases, we identified a statistically significant cluster at the ZIP-code 
level when evaluated in space (P < .05), but not when using the space-time scan statistic (I 
= .17). The cluster includes 13 ZIP codes in the Wilkes-Barre, Pennsylvania area (Figure 2). 
The Poisson probability of finding 9 cases in this area, where 3.05 cases were expected, is .
00029 (P-value).
Discussion
We found 89.5% sensitivity and 59% PPV of MPN reporting to the PCR as evaluated in this 
study, an expansion and update of an earlier ATSDR study in the Tri-County area of Carbon, 
Luzerne, and Schuylkill Counties, Pennsylvania. In this study, the expert panel review 
confirmed an MPN in 54% of the evaluated cases, which was slightly higher than the 
original ATSDR investigation. However, only 47% of the PV cases evaluated in this update 
were determined to be true cases compared to 53% in the original ATSDR investigation. A 
companion study, conducted in a demographically similar 4-county region of Pennsylvania, 
found 82% sensitivity and 47% PPV for PV only in 2001–2009.
These findings indicate that MPNs remain very difficult to diagnose. The 2008 WHO 
guidelines could improve PPV of diagnoses; however, because our study period ended in 
2009, the guidelines were not widely used or applied in this study. We also found that the 
inaccurate reporting was due to not distinguishing PV from other conditions, namely 
secondary polycythemia, and a lack either of JAK2 testing or documentation of such in the 
medical records. These results were surprising in view of the physician and hematologist 
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education programs and extensive outreach that were conducted in the Tri-County area after 
completion of the ATSDR study,4 and the current widespread availability of the JAK2 test. 
Among cases evaluated by the expert panel, the PPV of PV reporting was only 47%, 
indicating that many false cases of PV are still being reported to the PCR. However, PV 
sensitivity was 100%, indicating that physician education and outreach efforts regarding the 
importance of PV reporting may have attributed to the increased reporting of PV in the Tri-
County area. ET had better PPV than PV with a higher percentage of ET cases being 
confirmed as true cases.
Our estimated incidence rates are lower than rates calculated from the original PCR database 
reflect the reporting inaccuracies. The estimated PV incidence rate was 64% lower than the 
original rate, 2.5 (0.8–5.10) per 100,000 instead of 5.3, after correcting for sensitivity and 
PPV. According to the ATSDR study results, the annual incidence of confirmed PV was 
between 2.4 and 3.5 per 100,000 in Carbon, Luzerne, and Schuylkill Counties in 2001–2005. 
The wider range of values in this study reflects the variability associated with the findings 
based on the low response and review rate by the expert panel.
The original ATSDR study identified a statistically significant PV cluster in the Hazleton, 
Pennsylvania area with an incidence rate of 3.47; they found that the remainder of the Tri-
County area had an incidence rate of 0.81 and the total area had an incidence rate 1.25. We 
did not identify any clusters of PV by ZIP code or census tract. We found a cluster of ET 
cases in the Wilkes-Barre area, based on 9 cases, which was statistically significant in space, 
but not in the space-time model at the ZIP-code level. Given that we are evaluating a 9-year 
time period, we place more emphasis on the space-time results, rather than those considering 
space only. Two of the ET cases were diagnosed in 1 census tract in a 2-year time period. 
Again, while this was statistically significant, it is difficult to determine the importance of 
such a small number of cases. Thirteen of 99 (13%) ET cases were evaluated by the expert 
panel. One lived in Carbon County, 1 lived in Schuylkill County and 11 lived in Luzerne 
County and all 9 true cases were Luzerne County residents. When all expert panel–evaluated 
ET cases (n = 13) were included in the cluster analyses, no statistically significant clusters 
were identified; similarly no clusters were identified using only the ET cases reported to the 
PCR (data not shown). The cluster identified here could be an artifact because all of the true 
cases resided in 1 county; ET cases in Luzerne may have been more willing to participate 
than cases in other counties. It may also represent a real increase of disease in Luzerne 
County. A more complete evaluation of ET might elucidate whether a cluster of ET persist 
in the Tri-County area.
This study was limited by a low incidence rate and a low response rate. The national 
incidence of MPNs has been estimated at 2.1 per 100,000.10 Additionally, only 26% of 
identified cases participated, although rates were slightly higher for some diseases, including 
PV. We attempted to include deceased cases in this study, which was not done in the original 
study. The participation rate among family members of deceased cases was significantly 
lower than the participation rate among living cases. Another reason for the low overall 
participation rate may be that the Tri-County area has been subject to numerous disease 
investigations during the past 20 years, in part owing to the high number of environmental 
contaminants in the region. Not only was the original ATSDR study conducted in the Tri-
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County area, but nearly a dozen other studies have been conducted in recent years3–4, 
including some targeting the same cases who were asked to participate in this study. The Tri-
County residents may be suffering from “study fatigue” and are no longer interested in 
cooperating with study investigators. Although we made concerted efforts to contact and 
interview cases, we had few cases with complete interview data (5 PV and 6 ET cases). This 
was not enough information to provide any meaningful data on symptoms or past medical 
history.
Despite the low response rate, our study provides important information on the sensitivity 
and PPV of MPN reporting to the PCR. We used press releases in Northeast Pennsylvania to 
recruit participants and performed extensive casefinding at hematology/oncology offices in 
and around the Tri-County area. We believe that these efforts completely and accurately 
captured the extent of the MPN cases in the Tri-County area for the time period of interest. 
Of the evaluated cases, we found that very few true MPN cases (n = 3) were missed in the 
original PCR data set. The PCR’s additional casefinding efforts identified 3 true cases, 
indicating that the use of billing information in outpatient settings may be an effective way 
for the PCR to gather case information from offices not reporting MPNs. The true self-
identified ET case was from a facility with a hospital registrar in the Tri-County area. 
Outreach efforts regarding MPN reporting should potentially be expanded to hospital 
registrars, and not limited to physician offices.
Our updated and expanded study of MPNs in the Tri-County area identified continued low 
PPV for PV reporting, but better PPV for ET. These findings suggest the need for continuing 
physician and registrar education on diagnostic criteria, and increased use and interpretation 
of JAK2 testing for MPN diagnosis. Unlike the original study, we did not find any areas with 
a high occurrence of PV cases, although we did identify a cluster of ET cases (n = 9) in the 
Wilkes-Barre area in space, but not in space and time. The low case participation and case 
chart review rates may have led to sensitivity and PPV with wide confidence intervals and 
hampered our ability to identify statistically significant disease clustering.
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Study Participation Flow Chart Final MPN Study Case Ascertainment
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True ET Cases in the Tri–county Area ET Cluster ZIP Codes and Location of True ET Cases
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